San Antonio-based Rapamycin Holdings Inc. has secured U.S. patent approval for the pharmaceutical formulation of its eRapa compound — a critical benchmark in the company’s growth.
San Antonio-based Rapamycin Holdings Inc. has secured U.S. patent approval for the pharmaceutical formulation of its eRapa compound — a critical benchmark in the company’s growth.